Package Insert SEARCH
Medical calc categories
New Drug Approvals
Google Site SEARCH
Arterial Blood Gas (ABG) Analysis
Anion Gap / Serum Osmolality
Common Laboratory (LAB) Values
Conventional- S.I. Units
Cerebrospinal fluid analysis
Diseases Conditions Factsheets
Tests & Procedures
Adult Treatment Panel III
Opioids - Equianalgesic Dosages
Clinical concerns - Geriatric Pts
Renal Dosing Protocols
Important equations (four)
Continuing Education Links
Guest book (old)
Consumer Links (old section)
About this site
Benzodiazepine Dose Conversions (oral)
The authors make no claims of the accuracy of the information contained herein; and these suggested doses and/or guidelines are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this document shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE
CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.
Mechanism of Action - Benzodiazepines
Binds to stereospecific benzodiazepine receptors on the postsynaptic GABA neuron at several sites within the central nervous system, including the limbic system, reticular formation. Enhancement of the inhibitory effect of GABA on neuronal excitability results by increased neuronal membrane permeability to chloride ions. This shift in chloride ions results in hyperpolarization (a less excitable state) and stabilization.
: Depending on the agent, dosage reductions of 50% are required in mild to moderate impairment and most agents should be avoided in severe/acute liver disease. Refer to the specific package insert in all cases.
(Total daily oral dose in mg)
Alprazolam (Xanax ®)
: Immediate release: Effective doses are 0.5-4 mg/day in divided doses; the manufacturer recommends starting at 0.25-0.5 mg 3 times/day; titrate dose upward; maximum: 4 mg/day. Anxiety associated with depression: Immediate release: Average dose required: 2.5-3 mg/day in divided doses.
: Immediate release: Initial: 0.5 mg 3 times/day; dose may be increased every 3-4 days in increments
1 mg/day; many patients obtain relief at 2 mg/day, as much as 10 mg/day may be required.
: Short-acting. Peak level: 1-2 hours. Average half-life (variable): 12 hours (9-20 hours).
: 4 - 10 mg depending on indication.
: Treatment should be started with the lowest recommended dose. The maximum dose should not be exceeded. The usual dose is 3 mg twice or three times daily. In severe conditions up to 6 -12 mg twice or three times daily. Treatment should be as short as possible. The patient should be reassessed regularly and the need for continued treatment should be evaluated, especially in case the patient is symptom free. The overall duration of treatment generally should not be more than 8 -12 weeks, including a tapering off process. In certain cases extension beyond the maximum treatment period may be necessary; if so, it should not take place without re-evaluation of the patient's status.
: Short-acting. Peak level: 1-4 hours. Average half-life (variable): 20 hours (8-30 hours).
: 30 - 60 mg
Chlordiazepoxide (Librium ®):
: Oral: 15-100 mg divided 3-4 times/day.
I.M., I.V.: Initial: 50-100 mg followed by 25-50 mg 3-4 times/day as needed.
: I.M.: 50-100 mg prior to surgery.
Ethanol withdrawal symptoms
: Oral, I.V.: 50-100 mg to start, dose may be repeated in 2-4 hours as necessary to a maximum of 300 mg/24 hours. Note: Up to 300 mg may be given I.M. or I.V. during a 6-hour period, but not more than this in any 24-hour period.
: Long-acting. Peak level: 1-4 hours. Average half-life (variable): 100 hours
: ~300 mg
Clonazepam (Klonopin ®):
: Initial daily dose not to exceed 1.5 mg given in 3 divided doses; may increase by 0.5-1 mg every third day until seizures are controlled or adverse effects seen (maximum: 20 mg/day). Usual maintenance dose: 0.05-0.2 mg/kg; do not exceed 20 mg/day.
: 0.25 mg twice daily; increase in increments of 0.125-0.25 mg twice daily every 3 days; target dose: 1 mg/day (maximum: 4 mg/day)
: Long-acting. Peak level: 1-4 hours. Average half-life (variable): 34 hours (18-50 hours).
: 20 mg
Clorazepate (Tranxene ®):
: Regular release tablets (Tranxene® T-Tab®): 7.5-15 mg 2-4 times/day .
Sustained release (Tranxene®-SD): 11.25 or 22.5 mg once daily at bedtime.
: Initial: 30 mg, then 15 mg 2-4 times/day on first day; maximum daily dose: 90 mg; gradually decrease dose over subsequent days.
: Long-acting. Peak level: 0.5 -2 hours. Average half-life (variable): 100 hours
: 90 mg
Diazepam (Valium ®):
Anxiety/sedation/skeletal muscle relaxant
: Oral: 2-10 mg 2-4 times/day
I.M., I.V.: 2-10 mg, may repeat in 3-4 hours if needed.
Sedation in the ICU patient
: I.V.: 0.03 to 0.1 mg/kg every 30 minutes to 6 hours.
: I.V.: 5-10 mg every 10-20 minutes, up to 30 mg in an 8-hour period; may repeat in 2-4 hours if necessary.
Rapid tranquilization of agitated patient
(administer every 30-60 minutes): Oral: 5-10 mg; average total dose for tranquilization: 20-60 mg.
: Long-acting. Peak level (oral): 1-2 hours. Average half-life (variable): 100 hours
: ~40 mg
Flurazepam (Dalmane ®):
Short-term treatment of insomnia:
15-30 mg at bedtime
: Insomnia: Oral: 15 mg at bedtime; avoid use if possible.
: Long-acting. Peak level: 0.5 - 1 hour. Average half-life (variable): 100 hours (40-250 hours).
: 60 mg
Lorazepam (Ativan ®):
: 1-10 mg orally in 2-3 divided doses. Usual dose: 2-6 mg/day in divided doses. Initial dose should not exceed 2 mg in debilitated patients.
: 2-4 mg orally at bedtime.
: I.V.: Up to 0.05 mg/kg; maximum: 4 mg/dose.
: 4 mg IV over 2 to 5 minutes. May repeat in 10-15 minutes. Usual maximum dose: 8 mg.
: Short-acting. Onset of action: Hypnosis: I.M.: 20-30 minutes. Sedation: I.V.: 5-20 minutes. Anticonvulsant: I.V.: 5 minutes, oral: 30-60 minutes. Average half-life (variable): 15 hours (8-24 hours).
: 10 mg (oral)
: 10-30 mg 3-4 times/day.
15-30 mg 3-4 times/day.
: 15-30 mg
: Short-acting. Peak level: 1-4 hours. Average half-life (variable): 8 hours (3-25 hours).
: 120 mg
Temazepam (Restoril ®):
Short-term treatment of insomnia
15-30 mg at bedtime.
: Intermediate-acting. Peak level: 2-3 hours. Average half-life (variable): 11 hours (3-25 hours).
: 30 mg
Benzodiazepine Equivalence Charts:
Arana and Rosenbaum, Handbook of Psychiatric Drug Therapy, 4th Edition, 2000.
Clinical Handbook of Psychotropic Drugs, 4th revised edition, Bezchlibnyk-Butler et al. editors (Clarke Insitute of Psychiatry, Toronto), Hogrefe & Huber.
Gelenberg AJ, Bassuk EL. The Practitioner's Guide to Psychoactive Drugs. Springer, 1997 - 536 pages (page 234).
Hughes W. Clinical Pharmacy. Macmillan Education AU, Dec 15, 2001 - 512 pages (page 167).
Ruiz P, Strain EC. Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook. Lippincott Williams & Wilkins, Apr 15, 2011 - 1074 pages (chapter 35: pages 503-504).
Substance Use Disorders: A Practical Guide By Stuart Gitlow 2nd edition.
Tyrer PJ, Silk KR. Cambridge Textbook of Effective Treatments in Psychiatry. Cambridge University Press, Jan 24, 2008 - 920 pgs (pg 301).
Listed dosages are for -
Adult patients ONLY
. PLEASE READ THE
CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER. GlobalRPH does not directly or indirectly practice medicine or provide medical services and therefore assumes no liability whatsoever of any kind for the information and data accessed through the Service or for any diagnosis or treatment made in reliance thereon.
David F. McAuley, Pharm.D., R.Ph
. GlobalRPh Inc.
Medical Calculators - A thru Z
Lab Values - A thru Z
This site complies with the
HONcode standard for trustworthy health